Ensign vs Healthcare Services
ENSG and HCSG side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ENSG and HCSG compare
Ensign is the larger company, worth 6.5 times as much as Healthcare Services ($10.9B against $1.7B).
On earnings, Healthcare Services is cheaper: it trades at 14.3× trailing earnings, against 29.2× for Ensign.
Ensign grew revenue faster over the last twelve months (18.9% versus 5.2% for Healthcare Services).
Ensign keeps more of each dollar of sales as profit, with a net margin of 6.9% compared with 6.6% at Healthcare Services.
Ensign pays a dividend yielding 0.14%; Healthcare Services does not pay one.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ENSG | HCSG |
|---|---|---|
| Size and price | ||
| Market cap | $10.9B | $1.7B |
| Share price | $186.32 | $24.52 |
| Change, 1 year | 0.37% | 30.4% |
| Change, 5 years | 124% | 24.6% |
| Beta (5Y) | 0.46 | 0.76 |
| Employees | 46K | 36K |
| StockData Score | ||
| Total score | 19 | 19 |
| Valuation score | 0 | 6 (better) |
| Growth score | 5 (better) | 4 |
| Performance score | 6 (better) | 3 |
| Health score | 5 | 6 (better) |
| Dividend score | 3 (better) | 0 |
| Valuation | ||
| P/E | 29.2× | 14.3× (better) |
| P/S | 2.0× | 0.9× (better) |
| P/B | 4.4× | 3.2× (better) |
| EV/EBITDA | 18.4× | 9.1× (better) |
| P/FCF | – | 11.3× |
| PEG | 2.10 | 0.69 (better) |
| FCF yield | – | 8.8% |
| Fair value | $151.76 | $33.57 |
| Margin of safety | −22.8% | 27.0% (better) |
| Growth | ||
| Revenue growth (TTM) | 18.9% (better) | 5.2% |
| Revenue growth, 5Y average | 16.1% (better) | 0.86% |
| Net income growth (TTM) | 17.3% | 1037% (better) |
| EPS growth (TTM) | 15.8% | 1129% (better) |
| EPS growth, 5Y average | 13.8% (better) | −9.3% |
| Profitability | ||
| Gross margin | 20.7% (better) | 17.1% |
| Operating margin | 8.5% | – |
| Net margin | 6.9% (better) | 6.6% |
| FCF margin | – | 8.0% |
| Return on equity | 17.0% | 24.7% (better) |
| Return on invested capital | 17.7% | – |
| Financial health | ||
| Debt / equity | 0.06 (better) | 0.00 |
| Net debt / EBITDA | −0.31 | – |
| Interest coverage | 60.0× | – |
| Current ratio | 1.21 | 3.02 (better) |
| Altman Z-score | 3.71 | 6.74 (better) |
| Piotroski F-score | 6 | 8 (better) |
| Dividends and buybacks | ||
| Dividend yield | 0.14% | – |
| Payout ratio | 3.9% | – |
| Years of dividend growth | 15 | – |
| Dividend growth, 5Y average | 4.5% | – |
| Buyback yield | 0.37% | 5.5% (better) |
| Shareholder yield | 0.51% | 5.5% (better) |
| Ownership | ||
| Held by institutions | 90.6% | 106% |
| Held by insiders | 3.6% | 1.3% |
| Insider net buying, 12 months | −$13.6M | −$3.4M (better) |
| Short interest, % of float | 2.6% | 3.9% |
Go deeper
- ENSG stock overview
- ENSG income statement
- ENSG valuation and score
- HCSG stock overview
- HCSG income statement
- HCSG valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.